Lisa Bright

Lisa Bright

Executive Partner

Lisa is an Executive Partner at Syncona Investment Management Ltd, and serves as Chair of Syncona portfolio company Resolution Therapeutics.

Lisa is a senior commercial leader and board member with over 30 years’ experience in biopharmaceuticals, serving in executive and general management roles where she has developed expertise in launching innovative specialty medicines. Most recently Lisa served as President International and Chief Commercial and Corporate Affairs Officer for Intercept Pharmaceuticals Inc. where she established the global commercial footprint and launch for an orphan drug. Previously, Lisa held a variety of senior roles at Gilead Sciences as VP Head International Government Affairs, VP Head HCV International Launch Planning, VP Head Northern Europe and VP and General Manager UK. Prior to that, at GlaxoSmithKline she was VP Commercial Strategy International, VP General Manager New Zealand, and VP Head Primary Care Sales.

In addition to her role at Resolution, Lisa currently serves on the Boards of several public and private companies including Ascendis Pharma AS, Dechra Pharmaceuticals Plc, and Immedica Pharma AB and also is on the Strategic Advisory Board for DRI Capital. She holds a B.Sc.Hons in Pharmacology from University College London.

Syncona portfolio companies

  • Resolution Therapeutics (Chair)
Chris Hollowood

Chris Hollowood

Chief Executive Officer
Roel Bulthuis

Roel Bulthuis

Managing Partner, Head of Investments
Rolf Soderstrom

Rolf Soderstrom

Chief Financial Officer
Edward Hodgkin

Edward Hodgkin

Managing Partner
Alasdair Moodie

Alasdair Moodie

General Counsel
Annabel Clark

Annabel Clark

Head of Investor Relations and Communications
Andrew Cossar

Andrew Cossar

Executive Partner, Head of Strategic Transactions
Fiona Langton-Smith

Fiona Langton-Smith

Chief Human Resources Officer